Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 09/19/24
End: 06/30/28
Due: 06/30/29
Phase: N/A
Priority: Normal
Start: 10/31/25
End: 12/31/27
Due: 12/31/28
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia. | NCT06927466 | Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. | user2@example.com | None | 2024-09-19 | 2028-06-30 | 2029-06-30 | - | - | 2025-07-14 |
| A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma. | NCT06970496 | Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. | user2@example.com | None | 2025-10-31 | 2027-12-31 | 2028-12-31 | - | - | 2025-07-14 |